PARNAX LAB LTD. is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 163 | 168 | 189 | 188 | 249 |
| EBITDA (ex other income) | 23 | 23 | 24 | 27 | 26 |
| margin % | 14.1 | 13.7 | 12.5 | 14.3 | 10.4 |
| Owners' profit | 8 | 9 | 10 | 12 | 12 |
| EPS, as reported (₹) | 9.70 | 7.80 | 8.38 | 10.05 | 10.27 |
| ROE % · ROCE % | 17.1 · 24.1 | 13.9 · 21.0 | 13.0 · 16.3 | 13.9 · 18.2 | 12.4 · 16.4 |
| Debt / equity (x) | 1.36 | 0.82 | 0.99 | 0.73 | 0.78 |
| Cash from operations | 9 | 21 | 16 | 32 | 8 |
| Capex | (16) | (10) | (32) | (19) | (17) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50 | 48 | 40 | 49 | 53 | 63 | 63 | 70 |
| Profit before tax | 5 | 5 | 1 | 4 | 4 | 5 | 3 | 3 |
| Net profit | 4 | 3 | 1 | 3 | 3 | 4 | 3 | 2 |
| EPS (₹) | 3.47 | 2.97 | 1.06 | 2.55 | 2.85 | 3.15 | 2.37 | 1.90 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Newspaper ad for 44th AGM, e-voting and book closure | compliance | minimal | — | — |
| 7 Sept 2026 · Notice of 44th AGM on September 29, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Parnax Lab files 44th Annual Report for FY 2025-26; AGM on Sep 29, 2026 | general | medium | — | — |
| 26 Aug 2026 · Book closure notice for Parnax Lab 44th AGM on Sept 29, 2026 | corporate actions | low | — | — |
| 26 Aug 2026 · Board approves revised Directors Report for FY26 | board shareholder meetings | low | — | — |
| 14 Aug 2026 · Q1 FY27: standalone PAT jumps to Rs 84.54L, new auditor proposed, AGM Sep 29 | results | high | — | — |
| 14 Aug 2026 · Promoter Mihir Shah receives 3.77 lakh shares as gift from Baiju Shah | ownership changes | medium | — | — |
| 14 Aug 2026 · Promoter Prakash Shah gets 3,61,872 shares via gift from fellow promoter Ila Shah | ownership changes | medium | — | — |
| 14 Aug 2026 · Promoter Prakash Shah receives 3.61 lakh shares as gift from fellow promoter Ila Shah | ownership changes | low | — | — |
| 14 Aug 2026 · Parnax Lab: Promoter Mihir Shah receives 3.77 lakh shares as gift from Baiju Shah | ownership changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| CIPLA LTD |
| 1,10,352 |
| 32.7 |
| 3.20 |
| 16.9 |
| 11.2 |
| 14.7 |
| 8.0 |
| 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.4 | 28.9 | 32 of 169 | 82% |
| P/B | 1.5 | 3.3 | 35 of 163 | 78% |
| ROCE | 12.1 | 10.8 | 83 of 183 | 55% |
| ROE | 12.4 | 10.4 | 67 of 171 | 61% |
| Debt / Equity | 0.8 | 0.1 | 153 of 171 | 11% |
| EBITDA margin | 9.6 | 17.5 | 123 of 165 | 26% |
| Revenue growth | 42.0 | 16.3 | 26 of 161 | 84% |
| Profit growth | (25.4) | 30.9 | 118 of 158 | 26% |
| Market cap | 146 | 839 | 125 of 182 | 32% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
